DelveInsight’s Drug-Eluting Stents market report provides a thorough comprehension of Drug-Eluting Stents and historical and forecasted Drug-Eluting Stents market trends in the 7MM (the United States, EU5 (Germany, France, Spain, Italy, and the United Kingdom), and Japan).
Some of the Key Highlights from the Drug-Eluting Stents Market Report
The major companies active in the Drug-Eluting Stents market include Abbott, Braun Melsungen AG, Biosensors International Group, Ltd, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Terumo Corporation, Medtronic, MicroPort Scientific Corporation, Lepu Medical, Cook, Medinol Ltd, Cardinal Health, among others.
The FDA-approved Drug-Eluting Stents available in the market include EluNIR, SYNERGY™ XD, XIENCE SIERRA, Coroflex® ISAR NEO, BA9™, Orsiro, and several others.
SYNERGY XD by Boston Scientific Corporation is a bioabsorbable everolimus-eluting stent of the next generation.
EluNIR by Medinol is the first drug-eluting stent made of elastomeric material. It’s made from a thin cobalt-chrome alloy. Ridaforolimus Eluting Coronary Stent System is a stent known for its unique flexibility, conformability, and scaffolding.
The Drug-Eluting Stents market is segmented by Type, Scaffold, and End Users.
Request for the Webex demo of the report @ Drug-Eluting Stents Market Outlook
Drug-Eluting Stents: Overview
Stents are small, expandable tubes that are inserted following percutaneous coronary intervention (PCI) to keep arteries open and improve blood flow. Stents are divided into two types: bare-metal stents and drug-eluting stents. Drug-Eluting Stents are coated with medications that slowly elute to prevent scar tissue buildup in the artery lining.
Drug-Eluting Stents Market
The total Drug-Eluting Stents market size is segmented by type, which includes coronary and peripheral stents. The Drug-Eluting Stents market is expected to grow due to a shift in preference for drug-eluting stents over angioplasty. The Drug-Eluting Stents market is expected to grow due to a change in preference for drug-eluting stents over angioplasty. The growing burden of the elderly population, combined with a sedentary lifestyle, is expected to increase the prevalence of atherosclerosis, thereby fueling the Drug-Eluting Stents market. Furthermore, the demand for minimally invasive procedures is a driving factor.
Find out which player or device is going to get the maximum share @ Drug-Eluting Stents Market Size
Drug-Eluting Stents Key Companies
Abbott
Braun Melsungen AG
Biosensors International Group, Ltd
BIOTRONIK SE & Co. KG
Boston Scientific Corporation
Terumo Corporation
Medtronic
MicroPort Scientific Corporation
Lepu Medical
Cook
Medinol Ltd
Cardinal Health
Drug-Eluting Stents Market Drivers
Increase in prevalence of artery blockage due to sedentary lifestyle and growing geriatric population
Technological advancement in the field of drug-eluting stenting
Drug-Eluting Stents Market Barriers
The risk associated with the stents
The dearth of skilled healthcare professionals
Drug-Eluting Stents Unmet Needs
Incomplete inhibition of restenosis (especially in complex lesions)
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-26
Drug-Eluting Stents Key Companies: Abbott, Braun Melsungen AG, Biosensors International Group, Ltd, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Terumo Corporation, Medtronic, MicroPort Scientific Corporation, Lepu Medical, Cook, Medinol Ltd, Cardinal Health, among others.
Tools Used: PEST Analysis
KOL’s Views
Table of Contents
1.
Key Insights
2.
Executive Summary of Drug-Eluting Stents
3.
Drug-Eluting Stents: Background and Overview
4.
Drug-Eluting Stents: Regulatory Framework
5.
Drug-Eluting Stents: Reimbursement Scenario
6.
Drug-Eluting Stents Company Profiles
7.
Drug-Eluting Stents: Competitive Analysis of Listed Products
8.
Drug-Eluting Stents: KOL Views
9.
Drug-Eluting Stents: Market Analysis in 7MM
10.
Country-Wise Market size of Drug-Eluting Stents in 7MM
11.
Drug-Eluting Stents Market Dynamics
12.
PEST Analysis
13.
Conclusion and Future perspective
14.
Appendix
15.
DelveInsight Capabilities
16.
Disclaimer
17.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Coronary Stents Market
Get a comprehensive analysis of Coronary Stents pipeline devices and key companies, including Medtronic, Abbott, Boston Scientific Corporation, Biosensors International Group, Ltd., BIOTRONIK SE & Co. KG, B. Braun Melsungen AG, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/